On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated
